- Poster presentation
- Open Access
Raynaud and digital ulcers in patients with juvenile systemic sclerosis: ambulatory iloprost protocol. A single center experience
© Guedes et al; licensee BioMed Central Ltd. 2014
- Published: 17 September 2014
- Calcium Channel Blocker
- Winter Season
- Center Experience
- Ulcer Healing
- Severe Side Effect
Raynaud Phenomenon (RP) and digital ulcers (DU) are the main clinical manifestation of vasculopathy secondary to Juvenile Systemic Sclerosis (jSSc) . Accepted treatment for RP is calcium channel blockers. Iloprost is indicated if active ulcers are present or if RP is refractory to treatment.
The aim of this study was to access the safety and efficacy of ambulatory treatment with intravenous prostanoides in children with RP and DU secondary to jSSc.
Three patients with jSSc and active digital ulcers were treated with intravenous iloprost . Our protocol establishes two treatments in the cold months: one in the beginning and the second 3 months later, of a continuous five day intravenous infusion(iv) of iloprost in a dose of 0.4- 0,6 mg/kg/min perfusion through an elastomeric pump.
Since 2007 we treated three patients with jSSc and active digital ulcers: two girls, 12 and 13 years, and a boy of 18 months old at time of first treatment. A total of 19 treatments of iv. iloprost were done, 15 of these in ambulatory basis with the elastomeric pump
Outcomes were good with a reduced number and severity of RP attacks in all patients, and reduced pain associated with RP and DU. No disabling or severe side effects were observed. Two patients, the girls, had no more active digital ulcers after the second treatment with a follow-up of 2 and 3 years respectively. One patient, male, has recurrent digital ulcers, but number has decreased from 4 to 1 not interfering with daily activities.
Iloprost iv. perfusion with the elastomeric pump at ambulatory is a safe and effective treatment for patients with refractory RP to calcium channel blockers and in patients with digital ulcers. The authors suggest two treatments in the winter season with reduction of number and severity of R and ulcer healing.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.